What are the functions and efficacy of lapatinib? What diseases does it mainly treat?

Lapatinib is an oral small molecule targeted drug that is a tyrosine kinase inhibitor that mainly targets HER2 (human epidermal growth factor receptor 2) and EGFR (epidermal growth factor receptor). By simultaneously inhibiting the signaling pathways of these two receptors, lapatinib can effectively block the growth, division and spread of cancer cells. This mechanism makes it more effective in the treatment of certain HER2-positive tumors, especially for patients who are ineffective or resistant to traditional anti-HER2 treatments.

The current main indication of lapatinib is the treatment of HER2-positive advanced or metastatic breast cancer, especially in combination with capecitabine (Capecitabine) for patients who have failed previous treatments including trastuzumab (Herceptin). In addition, it can be used in combination with aromatase inhibitors to treat postmenopausal patients with hormone receptor-positive and HER2-positive breast cancer. Because it is an oral drug, the convenience of treatment also provides patients with more choices.

In addition to breast cancer, studies are also exploring the potential effect of lapatinib on other HER2 overexpressed tumor types, such as gastric cancer, cholangiocarcinoma, etc., but these indications have not yet been widely approved. Because it can cross the blood-brain barrier, some studies have also tried to apply it in the treatment of brain metastases from HER2-positive breast cancer, although the efficacy still needs to be further confirmed. This feature also gives it potential advantages in certain clinical scenarios.

In general, lapatinib is a dual-target inhibitor targeting HER2 and EGFR. It is mainly used to treat HER2-positive breast cancer, especially for patients who are resistant to traditional treatments or cannot tolerate intravenous therapy. Patients need to be under the guidance of a doctor during use, develop a reasonable treatment plan based on individual conditions, and pay close attention to adverse reactions after medication to improve treatment effects and quality of life.

Reference materials:https://medlineplus.gov/druginfo/meds/a607055.html